Akèy › Maladi otoim
Etid klinik pou Maladi otoim ap rekrite nan Etazini
76 etid pou Maladi otoim ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX21 etid
- Washington, DC19 etid
- New York City, NY19 etid
- Philadelphia, PA16 etid
- Durham, NC15 etid
- Boston, MA13 etid
- Los Angeles, CA12 etid
- Chicago, IL12 etid
- Dallas, TX9 etid
- Cleveland, OH8 etid
- Atlanta, GA8 etid
- Milwaukee, WI8 etid
- Portland, OR8 etid
- Cedar Rapids, IA7 etid
- Seattle, WA7 etid
- Orange, CA7 etid
- San Francisco, CA7 etid
- Pittsburgh, PA7 etid
- Louisville, KY6 etid
- The Bronx, NY6 etid
- Kansas City, KS6 etid
- Jacksonville, FL6 etid
- Salt Lake City, UT6 etid
- Rochester, MN6 etid
- Mountain View, CA6 etid
- Miami, FL6 etid
- Memphis, TN6 etid
- Baltimore, MD6 etid
- Ann Arbor, MI6 etid
- San Diego, CA5 etid
- Sacramento, CA5 etid
- Aurora, CO5 etid
- Nashville, TN5 etid
- New Haven, CT5 etid
- Worcester, MA4 etid
- Kansas City, MO4 etid
- Greenville, NC4 etid
- Indianapolis, IN4 etid
- Minneapolis, MN4 etid
- Rochester, NY4 etid
Pa eta
- Alabama5 etid
- Arizona6 etid
- Arkansas3 etid
- Colorado8 etid
- Connecticut5 etid
- Distrik Columbia6 etid
- Florid20 etid
- Georgia10 etid
- Illinois14 etid
- Indiana4 etid
- Iowa7 etid
- Kalifòni27 etid
- Kansas7 etid
- Kentucky8 etid
- Maryland21 etid
- Massachusetts16 etid
- Michigan9 etid
- Minnesota9 etid
- Missouri7 etid
- Nebraska3 etid
- New Jersey5 etid
- New York24 etid
- North Carolina18 etid
- Ohio13 etid
- Oklahoma4 etid
- Oregon9 etid
- Pennsylvania21 etid
- South Carolina4 etid
- Tennessee10 etid
- Texas22 etid
- Utah7 etid
- Virginia6 etid
- Washington8 etid
- Wisconsin8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Ap rekriteFaz 2Volontè an sante akeyi
Laj 4 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT02579967Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT04097561Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Ap rekriteFaz 2
Laj 4 a 69 · Tout sèks · Mizajou Sep 28, 2026 · NCT04339777NIAID Centralized Sequencing Protocol
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 100 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT03206099Natural History of Bronchiectasis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT00943514Environmental Risk Factors for the Anti-synthetase Syndrome
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01276470Secukinumab Open Label Roll-over Extension Protocol
Ap rekriteFaz 4
Laj 6 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT04638647Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07621809A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 25, 2026 · NCT07541287Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Ap rekriteEtid obsèvasyon
1 Month – 100 Years · Tout sèks · Mizajou Sep 24, 2026 · NCT00246857Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Ap rekriteEtid obsèvasyon
Jiska laj 99 · Tout sèks · Mizajou Sep 24, 2026 · NCT00001350Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Ap rekriteFaz 2
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT00977977Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 21, 2026 · NCT07513181A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746Daratumumab in Primary Antiphospholipid Syndrome
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Sep 16, 2026 · NCT05671757METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
Ap rekriteFaz 2
Laj 18 a 69 · Tout sèks · Mizajou Sep 15, 2026 · NCT07699380A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 11, 2026 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318PS-002 for the Treatment of IgA Nephropathy in Adults
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07182227The Mycophenolate Pregnancy Registry
Ap rekriteEtid obsèvasyon
Tout laj · Fanm · Mizajou Sep 8, 2026 · NCT01733082Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.